• PND146 - MS PATIENTS’ PERCEPTION OF THE EFFECTS OF PR-FAMPRIDINE ON WALKING DISORDERS AND DAILY LIFE- RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PRM87 - CRITICAL EVALUATION OF VARIOUS DATA MINING ALGORITHMS USED FOR SIGNAL DETECTION IN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PRS85 - VALIDATION OF AN EASY-TO-COMPLETE QUESTIONNAIRE FOR STUDYING PREDICTORS OF ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2018, 00:00

  • PMU40 - LIVE BIRTH RATE (LBR), ONGOING PREGNANCY RATE (OPR) AND OVARIAN HYPERSTIMULATION SYNDROME (OHSS) RISK WITH ORIGINATOR VERSUS BIOSIMILAR RECOMBINANT FOLLITROPIN ALFA- A POOLED ANALYSIS OF CLINICAL TRIAL DATA

    Oct 1, 2018, 00:00

  • PHP40 - TRENDS IN THE INCLUSION OF NON-PHARMACEUTICAL HEALTH TECHNOLOGIES IN THE ISRAELI NATIONAL LIST OF HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.

    Oct 1, 2018, 00:00

  • PMU73 - EVIDENCE MAP OF ECONOMIC EVALUATIONS OF EXERCISE THERAPY PUBLISHED SINCE 2015

    Oct 1, 2018, 00:00

  • PHP52 - ACCESSIBILITY AND ACCESS TO ORPHAN DRUGS IN PORTUGAL- HOW FAR ARE WE?

    Oct 1, 2018, 00:00

  • PIN78 - UPTAKE OF THE SEASONAL INFLUENZA VACCINATION AMONGST A COHORT OF PHARMACISTS IN IRELAND

    Oct 1, 2018, 00:00

  • PRM148 - HEALTH TECHNOLOGY ASSESSMENT AGENCY APPRAISAL OF IMMUNO-ONCOLOGY CURE FRACTION SURVIVAL MODELLING

    Oct 1, 2018, 00:00

  • PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTS

    Oct 1, 2018, 00:00

  • PSY102 - MUCOPOLYSACCHARIDOSIS DRUG COVERAGE IN RUSSIA- EXPEDIENCY OF DRUG PROCUREMENT CENTRALIZATION

    Oct 1, 2018, 00:00

  • PCN256 - INDICATION-SPECIFIC PRICING IN ONCOLOGY- HOW WILL U.S. PAYERS DETERMINE VALUE AMID THIS GROWING TREND?

    Oct 1, 2018, 00:00

  • PMS17 - BUDGET IMPACT OF DENOSUMAB IN THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMU3 - SELF MEDICATION ATTITUDE, KNOWLEDGE, AND PERCEPTION

    Oct 1, 2018, 00:00

  • PUK14 - LOW-DOSE ORAL DESMOPRESSIN LYOPHILISATE IS A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS EXPERIENCING AT LEAST TWO NOCTURNAL MICTURITIONS

    Oct 1, 2018, 00:00

  • PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS- A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET

    Oct 1, 2018, 00:00

  • PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICING

    Oct 1, 2018, 00:00

  • PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET- OPPORTUNITIES FOR REFORM

    Oct 1, 2018, 00:00

  • PRM100 - WEIGHTED METHOD FOR ESTIMATING INCIDENCE OF HERPES ZOSTER IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY- CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITURE

    Oct 1, 2018, 00:00

  • PCP52 - AN ANALYTICAL FRAMEWORK FOR EFFICACY EVALUATION OF LIGHT THERAPY IN MOOD DISORDERS- THE LINKED MECHANISMS APPROACH

    Oct 1, 2018, 00:00

  • PRS98 - SLEEP DISTURBANCE AND FATIGUE AS CONSEQUENCES OF COUGH AND MUCUS PRODUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE- INSIGHTS FROM A PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PCP43 - HEALTH IMPACT MODELLING (HIM)- CONCEPT, APPROACH AND REAL-WORLD DATA NEEDS FOR THE ESTIMATION OF POTENTIAL EFFECTIVENESS PROVIDED BY A PHARMA COMPANY PORTFOLIO

    Oct 1, 2018, 00:00

  • PUK7 - ASSOCIATION BETWEEN ADHERENCE TO RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES- A POPULATION BASED STUDY USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP251 - PUBLIC-PRIVATE CONTRIBUTION TO BIOPHARMACEUTICAL DISCOVERIES- A BIBLIOMETRIC ANALYSIS OF BIOMEDICAL RESEARCH IN UK

    Oct 1, 2018, 00:00

  • PND83 - HEALTH RESOURCE UTILIZATION ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES- A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIES

    Oct 1, 2018, 00:00

  • PHP61 - THE NEW AIFA INNOVATION FRAMEWORK TO RECOGNIZE INNOVATIVE DRUGS- A PRELIMINARY ANALYSIS OF KEY DRIVERS OF EVALUATION

    Oct 1, 2018, 00:00

  • PCN257 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) FOLLOWING INITIAL PLATINUM THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)- A MEDICAL RECORD REVIEW IN GERMANY

    Oct 1, 2018, 00:00

  • PHP95 - THE STUDY OF DYNAMIC ADJUSTMENT MECHANISM OF MEDICAL SERVICE PRICE IN CHINA

    Oct 1, 2018, 00:00

  • PND118 - PERCEPTIONS AND NEEDS OF PATIENTS WITH MIGRAINE IN GREECE- A FOCUS GROUP STUDY

    Oct 1, 2018, 00:00

  • PCP14 - VALUE FRAMEWORKS AND PRICING SETTING; CAN THEY CO-EXIST?

    Oct 1, 2018, 00:00

  • PRM231 - REPORT OF NETWORK META-ANALYSIS GEOMETRY- A SYSTEMATIC REVIEW AND METRICS RECOMMENDATION

    Oct 1, 2018, 00:00

  • PIN120 - VARIATIONS IN RABIES VACCINE ADMINISTRATION AMONG RABIES EXPOSURE AND BITE VISITS IN UNITED STATES EMERGENCY DEPARTMENT SETTINGS

    Oct 1, 2018, 00:00

  • PRM85 - MACHINE LEARNING AND NATURAL LANGUAGE PROCESSING TO POWER LITERATURE SEARCH FOR TIMELY, MEANINGFUL RESULTS

    Oct 1, 2018, 00:00

  • PRM1 - VALIDATION OF ALTERNATIVE “SURROGATE” CLINICAL ENDPOINTS IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PIN45 - COST-EFFECTIVENESS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS

    Oct 1, 2018, 00:00

  • PMS39 - THRESHOLD PRICES FOR IMPROVEMENTS IN KNEE AND HIP REPLACEMENT- EVIDENCE FROM ROUTINELY COLLECTED DATA

    Oct 1, 2018, 00:00

  • DS3 - REGORAFENIB IN METASTATIC COLORECTAL CANCER- COST-EFFECTIVENESS ANALYSIS BASED ON PROPENSITY SCORE WEIGHTED COHORT OF CZECH REGISTRY

    Oct 1, 2018, 00:00

  • PHP168 - TRUMP’S PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST

    Oct 1, 2018, 00:00

  • PRS33 - THE CLINICAL AND ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS IN ALGERIA

    Oct 1, 2018, 00:00

  • PND109 - SICKLE-CELL DISEASE RELATED HOSPITALIZATIONS IN FRANCE - A REGIONAL DESCRIPTIVE ANALYSIS FROM THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE IN 2016

    Oct 1, 2018, 00:00

  • PRM138 - THE DIVE FRAMEWORK FOR USING DIFFERENT TYPES OF INFORMATION IN ESTIMATING LIFETIME CLINICALLY PLAUSIBLE EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PSS29 - SECUKINUMAB VERSUS ETANERCEPT FOR THE TREATMENT OF PSORIASIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD1 - POST-ND-YAG LASER COMPLICATIONS IN CATARACT PATIENTS TREATED FOR POSTERIOR CAPSULAR OPACIFICATION- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN6 - SYSTEMATIC LITERATURE REVIEW OF EFFICACY SAFETY DATA FOR THE TREATMENT OF PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PRM36 - COST-EFFECTIVENESS AND BUDGET IMPACT THRESHOLDS IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS- A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PRM53 - THE USE OF PROXY MARKERS TO DEFINE DISEASE STAGE IN PATIENTS WITH MALIGNANT MELANOMA- AN OBSERVATIONAL STUDY USING THE HOSPITAL EPISODE STATISTICS (HES) DATABASE IN ENGLAND

    Oct 1, 2018, 00:00

  • PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS- A RETROSPECTIVE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PND73 - THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS- AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PRM89 - DATABASE ANALYSIS OF A PSP (PATIENT SUPPORT PROGRAM) FOR PATIENTS USING INTERFERON BETA-1A FOR RELAPSING MULTIPLE SCLEROSIS IN BRAZIL

    Oct 1, 2018, 00:00

  • PCN239 - NICE AND THE CANCER DRUGS FUND- APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMU55 - CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE- THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN

    Oct 1, 2018, 00:00

  • PRM51 - A NEW CONCEPTUAL MODEL OF THE COST-EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PSY219 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMU49 - HEALTH INSURANCE COST OF PSORIASIS IN HUNGARY- COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PCV97 - HEARTH FAILURE IN VENETO REGION, ITALY- ANALYSIS OF THE THERAPEUTIC PATHWAYS AND CONSUMPTION OF HEALTH CARE RESOURCES

    Oct 1, 2018, 00:00

  • PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLY

    Oct 1, 2018, 00:00

  • PMH35 - ECONOMIC BURDEN OF SCHIZOPHRENIA IN EUROPE

    Oct 1, 2018, 00:00

  • PMS117 - A MULTIDSCIPLINARY STUDY ON HEALTH-RELATED QUALITY OF LIFE IN CLUBFOOT

    Oct 1, 2018, 00:00

  • PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

    Oct 1, 2018, 00:00

  • PCN126 - DIRECT COST STUDY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS- THE IMPACT OF THE METHODOLOGY

    Oct 1, 2018, 00:00

  • PRM211 - MITIGATING EMOTIONAL BURDEN OF CONDUCTING INTERVIEWS WITH PEDIATRIC PATIENTS AND/OR THEIR CAREGIVERS ON THE INTERVIEWER- FIRST-PERSON INTERVIEWER EXPERIENCES

    Oct 1, 2018, 00:00

  • PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • MD2 - NETWORK META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES ALLOWING FOR MULTIPLE TESTS AT MULTIPLE THRESHOLDS FOR HEALTHCARE POLICY AND DECISION MAKING

    Oct 1, 2018, 00:00

  • PCN297 - IMPACT OF ECONOMIC SANCTIONS ON ACCESS TO NONCOMMUNICABLE DISEASES MEDICINES IN THE ISLAMIC REPUBLIC OF IRAN

    Oct 1, 2018, 00:00

  • PRS61 - ASSESSMENT OF ASTHMA-DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY IN VENETO REGION

    Oct 1, 2018, 00:00

  • PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE- IMPACT ON HTA OUTCOMES AND PRICE

    Oct 1, 2018, 00:00

  • PMU41 - PAST, CURRENT AND EXPECTED NEED FOR HOME ARTIFICIAL NUTRITION IN PIEDMONT- RESOURCES NEEDED TO MAINTAIN A RECOGNIZED HIGH QUALITY LEVEL

    Oct 1, 2018, 00:00

  • PSY104 - CORE OBESITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF WEIGHT MANAGEMENT INTERVENTIONS

    Oct 1, 2018, 00:00

  • PIH13 - ABIRATERONE- A SINGLE-CENTRE EXPERIENCE

    Oct 1, 2018, 00:00

  • CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PMS78 - CHANGES IN THE PRICES OF INCUMBENT TNF-ALPHA INHIBITORS FOLLOWING THE MARKET ENTRY OF COMPETITORS

    Oct 1, 2018, 00:00

  • PSY109 - WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE

    Oct 1, 2018, 00:00

  • PMD79 - COST-EFFECTIVENESS OF ULTRASOUND-GUIDED CENTRAL VENOUS CATHETERISATION FROM THE GERMAN PAYER PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.

    Oct 1, 2018, 00:00

  • PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELAND

    Oct 1, 2018, 00:00

  • PRM19 - REPORTING FOLLOW-UP IN SURVIVAL ANALYSES- INFORMATIVE OR NOT?

    Oct 1, 2018, 00:00

  • PMD157 - ASSESSMENT OF IN VITRO DIAGNOSTIC REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES- IDENTIFIED HURDLES AND POSSIBLE SOLUTIONS.

    Oct 1, 2018, 00:00

  • PSS4 - IMPORTANCE OF PROPERLY ADJUSTING FOR HETEROGENEITY AMONG NETWORK META-ANALYSES CONSIDERING OUTCOMES WITH MULTIPLE PRE-DEFINED LEVELS- AN ILLUSTRATIVE EXAMPLE IN PSORIASIS

    Oct 1, 2018, 00:00

  • PSS69 - APPRAISAL OF PATIENT REPORTED OUTCOME INSTRUMENTS IN INFLAMMATORY ACNE

    Oct 1, 2018, 00:00

  • PHP215 - DANISH MEDICINE COUNCIL PROCESS OF ASSESSING NEW HOSPITAL MEDICINES– FIRST YEAR OF IMPLEMENTATION

    Oct 1, 2018, 00:00

  • PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICS

    Oct 1, 2018, 00:00

  • PRS104 - USING OF "THE FOOD HYPERSENSITIVITY FAMILY IMPACT” (FLIP) QUESTIONNAIRE FOR ASSESSMENT OF QUALITY OF LIFE OF FOOD-ALLERGIC CHILD'S FAMILY MEMBERS.

    Oct 1, 2018, 00:00

  • PMU104 - WHAT ARE THE VIEWS AND PERCEPTIONS OF THE GREEK POPULATION TOWARDS THE PHARMACEUTICAL INDUSTRY?

    Oct 1, 2018, 00:00

  • CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIAL

    Oct 1, 2018, 00:00

  • PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?

    Oct 1, 2018, 00:00

  • PRM28 - PERFORMANCE OF THE EARLY WARNING SYSTEM VITAL TO PREDICT UNANTICIPATED HIGHER-LEVEL OF CARE ADMISSION AND IN-HOSPITAL DEATH OF WARD PATIENTS

    Oct 1, 2018, 00:00

  • PMH46 - A NATIONAL COMPREHENSIVE SURVEY STUDY OF PARKINSON’S DISEASE PSYCHOSIS PATIENTS AND CAREGIVERS REGARDING TIME TO PARKINSON’S DISEASE PSYCHOSIS DIAGNOSIS AND TREATMENT INITIATION

    Oct 1, 2018, 00:00

  • PCN372 - EVIDENCE MAP OF PATIENT REPORTED OUTCOME STUDIES IN NON-HODGKIN LYMPHOMA SINCE 1960

    Oct 1, 2018, 00:00

  • PSS6 - USING RANDOMISED CONTROLLED TRIAL (RCT) DATA AS EXTERNAL CONTROL TO OBTAIN COMPARATIVE EFFECTIVENESS IN A BAYESIAN NETWORK META-ANALYSIS MODEL

    Oct 1, 2018, 00:00

  • PHP230 - EU5 MARKET ACCESS FOR MEDICINES APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Oct 1, 2018, 00:00

  • PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PND149 - FACTORS ASSOCIATED WITH THE CAREGIVERS’ INTENTION TO INSTITUTIONALIZE PERSONS WITH DEMENTIA

    Oct 1, 2018, 00:00

  • PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS

    Oct 1, 2018, 00:00

  • PIN129 - ADAPTING INFLUENZA PATIENT-REPORTED OUTCOMES (PRO) MEASURES TO MONITOR RESPIRATORY SYNCYTIAL VIRUS (RSV) SYMPTOM SEVERITY IN ADULTS- QUALITATIVE EVIDENCE OF KEY CONCEPTS AND CONTENT VALIDITY

    Oct 1, 2018, 00:00

  • PCN200 - COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE

    Oct 1, 2018, 00:00

  • PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE- A BUDGET IMPACT MODEL

    Oct 1, 2018, 00:00

  • PMU87 - HEALTH STATE UTILITY FOR COMORBID CONDITIONS- EVALUATING THE IMPACT OF DIFFERENT ESTIMATION METHODS

    Oct 1, 2018, 00:00

  • PRM225 - EVALUATING PREVIOUS MIGRAINE HEADACHE FREQUENCY STATISTICAL MODELLING APPROACHES USING AN INDEPENDENT DATASET FROM THE EVOLVE STUDIES IN EPISODIC MIGRAINE

    Oct 1, 2018, 00:00

  • PCV118 - FACTORS DETERMINING SELECTION OF APPROPRIATE PATIENTS FOR PCSK9 INHIBITORS IN EUROPEAN CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PSY79 - THE COST OF MAJOR BLEEDING EVENTS ASSOCIATED WITH ANTICOAGULATION TREATMENT – AN ESTIMATION OF THE CONTRIBUTION OF THE REVERSAL AGENTS TO THE OVERALL COST OF MAJOR BLEEDING IN A UK SETTING

    Oct 1, 2018, 00:00

  • QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA- A NATIONWIDE SURVEY

    Oct 1, 2018, 00:00

  • PIH9 - BACTERIOLOGICAL PROFILE AND ANTIBIOGRAM OF NEONATAL SEPSIS IN THE NEONATAL INTENSIVE CARE UNIT OF AN EGYPTIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PGI21 - COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN’S DISEASE FOR TURKEY

    Oct 1, 2018, 00:00

  • PMD56 - COST OF STENT-RETRIEVER MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • MO4 - COMPARING MIXTURE CURE MODELS WITH STANDARD PARAMETRIC MODELS WITHIN THREE- AND FIVE-STATE PARTITION SURVIVAL FRAMEWORKS

    Oct 1, 2018, 00:00

  • PCN296 - BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PSY89 - COSTS AND EFFECTS OF ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA- A PROSPECTIVE COHORT STUDY IN ITALY

    Oct 1, 2018, 00:00

  • PSS53 - ORIGINATOR AND GENERIC MARKET ACCESS PROTECTION STRATEGIES IN GERMANY USING DERMATOLOGY AS AN EXAMPLE

    Oct 1, 2018, 00:00

  • PSY22 - A REVIEW ON EPIDEMIOLOGY, RISK FACTORS AND TREATMENT PATTERNS IN MODERATE AND SEVERE PAINFUL DIABETIC NEUROPATHY AND POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PMS67 - DEVELOPMENT OF A PATIENT DECISION AID (PDA) FOR PATIENTS WITH RHEUMATOID ARTHRITIS THAT REDUCES DECISIONAL CONFLICT AND IMPROVES READINESS FOR TREATMENT DECISION MAKING

    Oct 1, 2018, 00:00

  • PIN27 - COMMUNITY-ACQUIRED PNEUMONIA HOSPITALIZATION COSTS IN THE ADULT POPULATION OF COSTA RICA FROM A PUBLIC HEALTH PERSPECTIVE OVER A 10 YEAR PERIOD (2005-2014)

    Oct 1, 2018, 00:00

  • PMS93 - ASSESSMENT OF PATIENTS’ ADHERENCE ON MTX USE- A PATIENT ASSOCIATION SURVEY.

    Oct 1, 2018, 00:00

  • PHP10 - PATIENTS’ INVOLVEMENT IN THE DEVELOPMENT OF TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND THE DESIGN OF CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PND97 - DEVELOPING STROKE SYSTEM CARE FOR LOW MIDDLE INCOME COUNTRIES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN’S LYMPHOMA- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PRM108 - EVALUATION OF CATARACT TREATMENT IN THE UNITED KINGDOM USING A PATIENT PATHWAY DISCREET EVENT SIMULATION MODEL

    Oct 1, 2018, 00:00

  • PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRS65 - ASSESSING THE IMPACT OF CONCURRENT PRESCRIPTION OPIOID USE ON ADHERENCE TO MAINTENANCE MEDICATIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A RETROSPECTIVE CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PND89 - BLOOD LOSS AND TRANSFUSION MANAGEMENT IN COMPLEX MULTI-LEVEL SPINE SURGERY IN EUROPE

    Oct 1, 2018, 00:00

  • PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS- A STUDY OF FIVE DEVELOPED COUNTRIES

    Oct 1, 2018, 00:00

  • PRS40 - COST-EFFECTIVENESS OF THE SQ® GRASS SUBLINGUAL IMMUNOTHERAPY (SLIT) TABLET IN A PAEDIATRIC POPULATION

    Oct 1, 2018, 00:00

  • PMD109 - A CANADIAN COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IMPLANTED AT TIME OF CATARACT SURGERY IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA

    Oct 1, 2018, 00:00

  • PCN22 - MARKETING AUTHORISATION PRACTICE OF THE EUROPEAN MEDICINES AGENCY (EMA) IN ONCOLOGICAL INDICATIONS

    Oct 1, 2018, 00:00

  • PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGS

    Oct 1, 2018, 00:00

  • PHP208 - PHYSICIANS’ IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA- A CROSS-SECTIONAL SURVEY

    Oct 1, 2018, 00:00

  • PMD67 - COST-CONSEQUENCE ANALYSIS OF A HEMOSTATIC FLOWABLE MATRIX ALONE OR IN COMBINATION FOR SPINE SURGERY PATIENTS

    Oct 1, 2018, 00:00

  • DS2 - EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN VERSUS RIVAROXABAN IN NON-VALVULAR ATRIAL FIBRILLATION- A COHORT STUDY IN THE SNDS FRENCH NATIONWIDE CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PIN50 - COST-EFFECTIVENESS OF GENDER-NEUTRAL NINE-VALENT HPV VACCINATION IN DENMARK

    Oct 1, 2018, 00:00

  • PCN119 - SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH NON-SMALL CELL LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PHP229 - EU5 MARKET ACCESS FOR MEDICINES WITH CONDITIONAL MARKETING AUTHORISATIONS

    Oct 1, 2018, 00:00

  • PRM90 - DIGITAL DASHBOARD FOR MAPPING PATIENT DISTRIBUTIONS

    Oct 1, 2018, 00:00

  • PMD183 - PREFERENCES FOR PRENATAL AND NEW BORN SCREENING- A SYSTEMATIC REVIEW OF DISCRETE CHOICE EXPERIMENTS

    Oct 1, 2018, 00:00

  • PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN27 - THE REAL-WORLD COST AND EFFECTIVENESS OF EVEROLIMUS IN METASTATIC BREAST CANCER IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMU67 - COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PRS10 - POPULATION HEALTH IMPACT OF OMALIZUMAB OVER 11 YEARS OF USE IN IRELAND IN MODERATE TO SEVERE ALLERGIC ASTHMA

    Oct 1, 2018, 00:00

  • PCN146 - INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOCYTIC LEUKEMIA (ALL)- ESTABLISHING A VALUE-BASED COST – PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PIH28 - ISAACUS DATA LAKE PRE-PRODUCTION PROJECT- CHILD PLACEMENT DECISION AND ITS COST DRIVERS

    Oct 1, 2018, 00:00

  • PMD73 - ECONOMIC IMPACT OF THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA ON HIP FRACTURE- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PMD84 - COST EFFECTIVENESS OF ENDOMETRIAL CANCER SCREENING AND PREVENTION - A SYSTEMATIC REVIEW OF ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PMD121 - EXPLORING THE DAILY CLINICAL PRACTICE IN MYOCARDIAL INFARCTION (MI) CARE IN EUROPE- SURVEY OF DIAGNOSTIC AND TREATMENT STRATEGIES FOR THEORETICAL PATIENTS

    Oct 1, 2018, 00:00

  • PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PIN114 - ASSESSMENT OF THE EFFICACY AND SAFETY OF VORICONAZOLE, COMPARED WITH AVAILABLE THERAPIES IN THE TREATMENT OF PATIENTS WITH INVASIVE ASPERGILLOSIS- A NETWORD META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY34 - HEMOPHILIA B - TREATMENT PATTERNS AND EPIDEMIOLOGY INSIGHTS FROM THE GERMAN HOSPITAL QUALITY REPORTS

    Oct 1, 2018, 00:00

  • PND127 - QUALITY OF LIFE IN PAEDIATRIC MULTIPLE SCLEROSIS- SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMH78 - CARE BURDEN AND QUALITY OF LIFE OF PRIMARY CAREGIVERS OF CHILDREN WITH INTELLECTUAL DISABILITIES IN MONGOLIA- THE MEDIATING EFFECT OF FAMILY STRENGTH

    Oct 1, 2018, 00:00

  • PCN230 - ARE NICE AND THE SMC DIVERGING IN THEIR ASSESSMENT OF ONCOLOGY DRUGS?

    Oct 1, 2018, 00:00

  • PRS91 - EVALUATING PATIENT PREFERENCES OF MAINTENANCE THERAPY FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN GERMANY- A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PMH74 - QUALITY OF LIFE ACCORDING TO TEMPORAL ILLICIT OPIOID USE AND RESPONDER RATE IN ADULTS RECEIVING BUPRENORPHINE DEPOT INJECTIONS (CAM2038) TO TREAT OPIOID USE DISORDER IN A 48-WEEK OPEN LABEL STUDY

    Oct 1, 2018, 00:00

  • PND102 - CARE PATHWAY DIVERSITY OF PATIENTS WITH MULTIPLE SCLEROSIS BETWEEN FRENCH REGIONS

    Oct 1, 2018, 00:00

  • PSY12 - REAL-WORLD EFFECTIVENESS STUDY OF FERRIC CARBOXYMALTOSE IN ANAEMIC PATIENTS

    Oct 1, 2018, 00:00

  • PIN91 - SHORT-TERM PROJECTIONS OF EXPENDITURE ON STD/AIDS DRUGS IN A SCENARIO OF NEW REGIME OF FISCAL AUSTERITY IN BRAZIL

    Oct 1, 2018, 00:00

  • PHP51 - UTILIZTION OF MONOCLONAL ANTIBODY IN CHINA- A STUDY FROM NATOINAL MARKET ACCESS VIEW

    Oct 1, 2018, 00:00

  • PMS64 - MULTIPLE SCLEROSIS AND WORKABILITY IN ITALY- THE ECONOMIC EFFECT OF NATALIZUMAB ON THE ABILITY TO WORK

    Oct 1, 2018, 00:00

  • PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANY

    Oct 1, 2018, 00:00

  • PMD82 - COST-EFFECTIVENESS OF INSULIN PUMP THERAPY IN ADULTS WITH TYPE 1 DIABETES MELLITUS (T1DM)- THE EMIPE STUDY - A REAL-LIFE EVIDENCE STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PSY206 - COMPLEMENTARY AND ALTERNATIVE MEDICINE FOR PAIN- USAGE, OUTCOMES AND COST

    Oct 1, 2018, 00:00

  • PSY45 - BUDGET IMPACT ANALYSIS OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE

    Oct 1, 2018, 00:00

  • PMD78 - COST-EFFECTIVENESS ANALYSIS OF REAL TIME CONTINOUS GLUCOSE MONITORING (RT-CGM) VS SELF MONITORING BLOOD GLUCOSE (SMBG) IN PATIENTS WITH TYPE 1 DIABETES IN SPAIN

    Oct 1, 2018, 00:00

  • PMD129 - TRENDS IN OUTCOMES ASSOCIATED WITH ACUTE ISCHEMIC STROKE IN A US COMMERCIAL INSURANCE POPULATION

    Oct 1, 2018, 00:00

  • PHP71 - HOW A NEW INNOVATION ASSESSMENT TOOL RELATES TO RECENT DRUG LAUNCHES FOR SPANISH NATIONAL ACCESS

    Oct 1, 2018, 00:00

  • PHP239 - THE INTRODUCTION AND IMPLICATIONS OF THE COST-CONTAINMENT MEASURE ‘THE SLUICE’ FOR EXPENSIVE INNOVATIVE DRUGS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)

    Oct 1, 2018, 00:00

  • PMU80 - ENHANCING MEDICATION ADHERENCE THROUGH AN ADHERENCE SUPPORT PROGRAM

    Oct 1, 2018, 00:00

  • HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAM

    Oct 1, 2018, 00:00

  • PCN173 - COST-EFFECTIVENESS OF NEW TRIPLET COMBINATIONS WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PIN81 - PHARMACISTS AS VACCINATORS- FIRST YEAR EXPERIMENTATION ON SEASONAL INFLUENZA VACCINATION IN FRANCE

    Oct 1, 2018, 00:00

  • PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIES

    Oct 1, 2018, 00:00

  • PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONS

    Oct 1, 2018, 00:00

  • PCN347 - EXPLORING THE IMPACT OF RADIOGRAPHIC PROGRESSIVE DISEASE AND FIRST SUBSEQUENT THERAPY ON HEALTH STATE UTILITY VALUES IN GERMLINE-BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSROC) PATIENTS ON OLAPARIB TABLETS ...

    Oct 1, 2018, 00:00

  • PRM166 - CONCEPTUALIZING A CORE DISCRETE EVENT SIMULATION MODEL TO EVALUATE THE ECONOMIC IMPACT OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    Oct 1, 2018, 00:00

  • PMS36 - SWITCH PATTERNS AND TOTAL HEALTHCARE COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIATIC ARTHRITIS- RESULTS FROM A US CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PMU54 - HOW MUCH DOES IT COST TO TRAIN A PHYSICIAN IN COLOMBIA?

    Oct 1, 2018, 00:00

  • PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES- A COMPARATIVE ASSESSMENT.

    Oct 1, 2018, 00:00

  • PND28 - A BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS VERSUS ALTERNATIVE HIGH EFFICACY TREATMENTS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) IN THE UNITED KINGDOM.

    Oct 1, 2018, 00:00

  • PMD127 - FIRST DO NO HARM? EXPLORING THE INTERPRETATION OF NICE DIAGNOSTIC ASSESSMENTS WITH COST SAVINGS AND QALY LOSS

    Oct 1, 2018, 00:00

  • PRM266 - 50 MILLION TESTS AND CONFOUNDING- THE PROMISES AND CHALLENGES OF BIG DATA

    Oct 1, 2018, 00:00

  • PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY- AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD

    Oct 1, 2018, 00:00

  • PRS103 - SMARTPHONE APPLICATION FOR THE ASTHMA RESEARCH IN CHILDREN AND ADOLESCENTS (ARCA) COHORT- A PILOT STUDY

    Oct 1, 2018, 00:00

  • PMH53 - THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS- ANALYSIS OF REAL WORLD EVIDENCE FROM THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRS16 - MODELED SURVIVAL GAINS OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGED ≥12 YEARS HETEROZYGOUS FOR F508DEL-CFTR AND A RESIDUAL FUNCTION MUTATION (F508DEL/RF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) TEZACA ...

    Oct 1, 2018, 00:00

  • PCV10 - RANDOMISED CONTROLLED TRIALS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) – A SYSTEMATIC REVIEW (SR) OF INCLUDED PATIENT POPULATIONS

    Oct 1, 2018, 00:00

  • PND156 - THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR) ON WORK- THE PATIENTS’ PERSPECTIVES

    Oct 1, 2018, 00:00

  • PIN35 - COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PND50 - SOCIAL RETURN ON INVESTMENT OF AN IDEAL APPROACH TO MULTIPLE SCLEROSIS WITHIN THE SPANISH NATIONAL HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PRM156 - THE IMPORTANCE OF ACCOUNTING FOR PARAMETER UNCERTAINTY AROUND THE SF-6D VALUE SETS AND ITS IMPACT ON STUDIES THAT USE THE SF-6D TO MEASURE HEALTH UTILITY

    Oct 1, 2018, 00:00

  • PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PCN343 - KNOWLEDGE ABOUT HUMAN PAPILLOMAVIRUS (HPV) IN PARENTS OF TEENAGE BOYS IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PDB18 - CLINICAL ECONOMIC EFFECTIVENESS OF USING VILDAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES UNDERGOING METFORMIN MONOTHERAPY WITH UNSATISFACTORY GLYCEMIC CONTROL

    Oct 1, 2018, 00:00

  • PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSS47 - A COHORT STUDY TO INVESTIGATE THE FACTORS ASSOCIATED WITH THE INTENTION TO USE ILLEGAL DRUG AMONG SAUDI STUDENTS

    Oct 1, 2018, 00:00

  • PMS96 - A DEMAND SURVEY ON PATIENT EDUCATION FOR PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PHP366 - DEVELOPMENT OF THE UNIFIED SYSTEM OF ASSESSMENT OF LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATIONS FOR THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PCP8 - BENELUXA INITIATIVE- WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?

    Oct 1, 2018, 00:00

  • PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN TUNISIA

    Oct 1, 2018, 00:00

  • PCN293 - WHAT IS THE VALUE OF REAL WORLD EVIDENCE IN ONCOLOGY IN HTA APPRAISALS IN ENGLAND, FRANCE, CANADA AND AUSTRALIA?

    Oct 1, 2018, 00:00

  • PHP343 - CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION, 2003-2016

    Oct 1, 2018, 00:00

  • PND105 - MULTIPLE SCLEROSIS- THE MAP OF PATIENT ACCESS TO DISEASE MODIFYING TREATMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PSY145 - IMPACT OF BIOSIMILAR ENTRY ON PRICE AND UPTAKE OF BRANDED BIOLOGICS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PMH69 - QUALITY OF LIFE ACCORDING TO RESPONDER RATE IN OPIOID DEPENDENT ADULTS RECEIVING TREATMENT WITH BUPRENORPHINE DEPOT INJECTIONS (CAM2038) VERSUS SUBLINGUAL BUPRENORPHINE/NALOXONE

    Oct 1, 2018, 00:00

  • PHP28 - EXPLANATIONS FOR THE DIFFERENCES BETWEEN EFFECTS ON ADHERENCE OF VALUE-BASED HEALTH INSURANCE DESIGNS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY6 - EFFECTIVENESS AND SAFETY OF PEGVISOMANT- META-ANALYSIS OF OBSERVATIONAL LONGITUDINAL STUDIES

    Oct 1, 2018, 00:00

  • PMS51 - COST-EFFECTIVENESS OF TOFACITINIB-CONTAINING SEQUENCES FOR RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN97 - ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFE

    Oct 1, 2018, 00:00

  • PMD77 - ECONOMIC EVALUATION OF SCREENING AND PREVENTION STRATEGIES FOR OVARIAN CANCER- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE- REALITIES, CHALLENGES AND PERSPECTIVES

    Oct 1, 2018, 00:00

  • PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS’ EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESIS

    Oct 1, 2018, 00:00

  • Disclosure Information

    Oct 1, 2018, 00:00

  • PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION- A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE US

    Oct 1, 2018, 00:00

  • PRS4 - ASSOCIATIONS OF DEPRESSION AND ANXIETY WITH A RISK OF EXACERBATIONS IN ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP

    Oct 1, 2018, 00:00

  • PCV111 - CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM PRESCRIBED ANTICOAGULANTS IN GERMANY

    Oct 1, 2018, 00:00

  • PND20 - INCIDENCE AND TREATMENT OF PATIENTS WITH STATUS EPILEPTICUS- AN ANALYSIS OF GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PRS1 - REAL-WORLD EVALUATION OF THE EFFECTIVENESS AND SAFETY OF PIRFENIDONE- FINDINGS FROM AN OBSERVATIONAL CHART REVIEW OF A LARGE COHORT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PIN69 - INDIRECT COSTS OF PNEUMOCOCCAL DISEASES IN POLAND- AN ANALYSIS BASED ON ABSENTEEISM DATA FROM SOCIAL INSURANCE INSTITUTION

    Oct 1, 2018, 00:00

  • PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • PDB53 - EVALUATING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL, INCIDENCE OF SEVERE HYPOGLYCEMIA, AND LONG-TERM HEALTH ECONOMIC OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSY117 - ASSESSMENT OF SOCIAL AND ECONOMIC BURDEN OF CHRONIC MYELOID LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PHP304 - INTRODUCTION OF EBM IN MEDICAL PROFESSIONALS' EDUCATION IN BULGARIA, IN ASSOCIATION WITH THE HTA PROCESS - A PILOT STUDY

    Oct 1, 2018, 00:00

  • PCN300 - MODERN TRENDS OF ORCHIECTOMY FOR PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PRM199 - STAKEHOLDER PERSPECTIVES ON CONDUCT AND USE OF PATIENT PREFERENCE STUDIES ALONG THE MEDICAL PRODUCT LIFECYCLE- RESULTS FROM FOCUS GROUPS

    Oct 1, 2018, 00:00

  • MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA- INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PMS99 - ACUTE EFFECTS OF DYNAMIC STRETCHING AFTER WARM UP ON SPRINTING ABILITY AND AGILITY AMONG ADOLESCENT BASKETBALL PLAYERS

    Oct 1, 2018, 00:00

  • PSY136 - A COMPARISON OF PR REQUIREMENTS FOR ORPHAN DRUGS IN 25 MARKETS

    Oct 1, 2018, 00:00

  • PHP143 - ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES OF INNOVATIVE MEDICINES ACCORDING TO THE CATALAN HEALTH SERVICE STANDARDS- A QUALITATIVE ASSESSMENT

    Oct 1, 2018, 00:00

  • PIN49 - THE COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN VERSUS CASPOFUNGIN FOR CANDIDEMIA AND INVASIVE CANDIDIASIS TREATMENT- AN EXPERIENCE FROM IRAN

    Oct 1, 2018, 00:00

  • PHP63 - MEASURES TO FIGHT ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLAND

    Oct 1, 2018, 00:00

  • PMS16 - EFFECT OF BISPHOSPHONATES ON PERIPROSTHETIC BONE MINERAL DENSITY LOSS AFTER HIP ARTHROPLASTY- AN INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PSY37 - SYSTEMATIC LITERATURE REVIEW ON THE WORLDWIDE EPIDEMIOLOGY OF PROPIONIC ACIDEMIA

    Oct 1, 2018, 00:00

  • PRS81 - PRESCRIBING PATTERN AND USE OF STEROIDS AMONG ASTHMATIC PATIENTS IN A TERTIARY CARE HOSPITAL

    Oct 1, 2018, 00:00

  • PIN57 - ECONOMIC ASSESSMENT OF EFFECTIVENESS AND SAFETY OF COMMON PRACTICE PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN A MULTIDISCIPLINARY HOSPITAL

    Oct 1, 2018, 00:00

  • CV3 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN GERMANY- APPLYING THE EFFICIENCY THRESHOLD

    Oct 1, 2018, 00:00

  • PCN283 - IDENTIFYING THE KEY CHALLENGES AFFECTING THE REIMBURSEMENT OF CAR-T THERAPIES IN THE EU5 USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PND137 - PATTERNS OF USE OF PROLONGED-RELEASE FAMPRIDINE AND PHYSIOTHERAPY AMONG PATIENTS WITH MS IN TWO LARGE MULTI-COUNTRY STUDY COHORTS

    Oct 1, 2018, 00:00

  • PHP113 - COMPARATIVE ANALYSIS OF BIOSIMILAR RITUXIMAB USAGE IN TREATING NON-HODGKIN LYMPHOMA AND RHEUMATOID ARTHRITIS- RESULTS FROM A MULTI-COUNTRY STUDY IN EUROPE

    Oct 1, 2018, 00:00

  • PIN62 - COST-EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINES IN A COHORT OF NEWBORNS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMS72 - ASSOCIATION BETWEEN HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN AND TIME-TO-TOTAL KNEE REPLACEMENT SURGERY AMONG COMMERCIALLY-INSURED PATIENTS WITH KNEE OSTEOARTHRITIS IN THE UNITED STATES- A RETROSPECTIVE STUDY WI ...

    Oct 1, 2018, 00:00

  • ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA

    Oct 1, 2018, 00:00

  • PSY212 - TREATMENT CHARACTERISTICS, QUALITY OF LIFE AND SLEEP PERFORMANCE OF LOCALISED NEUROPATHIC PAIN PATIENTS IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PMD106 - COST-EFFECTIVENESS OF LONG-LASTING INSECTICIDE-NETS FOR THE PREVENTION OF MALARIA IN RURAL AND URBAN MALARIOUS AREAS

    Oct 1, 2018, 00:00

  • PUK23 - EVALUATION OF THE PROGRAM OF NEPHROPROTECTION IN PATIENTS WITH RENAL DISEASE OF A COLOMBIAN INSURANCE COMPANY

    Oct 1, 2018, 00:00

  • PRS90 - ASSOCIATION BETWEEN SEVERE, MODERATE AND MILD EXACERBATIONS WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN COPD PATIENTS

    Oct 1, 2018, 00:00

  • PHP256 - MACHINE LEARNING TO IDENTIFY REAL-WORLD PATIENT CHARACTERISTICS ASSOCIATED WITH LENGTH OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PMS80 - PSORIATIC ARTHRITIS PREVALENCE IN PSORITIC PATIENTS- BRAZIL, CHILE AND COLOMBIA CASES

    Oct 1, 2018, 00:00

  • PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE - THE QUESTIONNAIRE ” TOP SCORE "

    Oct 1, 2018, 00:00

  • PCN150 - COST-EFFECTIVENESS ANALYSIS OF PHARMACOKINETIC-GUIDED (PK) 5-FLUOROURACIL (5-FU) DOSING WHEN COMBINED WITH LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) CHEMOTHERAPY FOR ADVANCED PANCREAS CANCER

    Oct 1, 2018, 00:00

  • PRM86 - INFLAMMATORY BOWEL DISEASE AND THE COST FOR SOCIAL SECURITY SYSTEM- ESTIMATING THE PREVALENCE AND THE DISABILITY BURDEN AMONG THE ITALIAN WORKER

    Oct 1, 2018, 00:00

  • PIH4 - HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH EXTREMELY PRETERM BIRTH IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMD49 - COST ANALYSIS OF USING THREE-DIMENSIONAL COMPLEX MAPPING CATHETER ABLATION VERSUS DRUG THERAPY FOR THE TREATMENT OF ATRIAL FIBRILLATION IN TURKEY

    Oct 1, 2018, 00:00

  • PCN60 - REAL-WORLD OVERALL SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDY

    Oct 1, 2018, 00:00

  • PRM139 - CHOOSING THE RIGHT SOFTWARE FOR HTA ECONOMIC MODELS- A COMPARISON OF FOUR PROGRAMMES RECOMMENDED BY THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE

    Oct 1, 2018, 00:00

  • PND98 - DETERMINING THE VALUE OF OCREVUS® (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Oct 1, 2018, 00:00

  • PRM252 - SIMULATED TREATMENT COMPARISON- IMPLICATIONS AND CHALLENGES OF AN ALTERNATIVE APPROACH TO ESTIMATING THE RELATIVE EFFICACY OF NIVOLUMAB VERSUS RELEVANT COMPARATOR CHEMOTHERAPY TREATMENTS FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA ...

    Oct 1, 2018, 00:00

  • PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIA

    Oct 1, 2018, 00:00

  • PHP317 - IDENTIFYING THE CHANGES REQUIRED IN HEALTH TECHNOLOGY ASSESSMENT SYSTEMS IF OUTCOMES ARE TO BE OPTIMIZED IN A DIGITAL WORLD WHERE PERSONALIZED DATA AND PRECISION MEDICINE COLLIDE

    Oct 1, 2018, 00:00

  • PCN69 - BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination- A Systematic Review of the Literature

    Oct 1, 2018, 00:00

  • PMU100 - MAPPING BENEFIT-RISK DECISION-MAKING PROCESSES AND IDENTIFYING DECISION POINTS WITH THE POTENTIAL TO INCLUDE PATIENT PREFERENCE INFORMATION THROUGHOUT THE MEDICAL PRODUCT LIFECYCLE

    Oct 1, 2018, 00:00

  • PCN140 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VS CRIZOTINIB IN FIRST LINE ANAPLASTIC LYMPHOMA KINASE POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS6 - EFFECTIVENESS OF BIOSSIMILARS UNDER HOSPITAL PHARMACY MANAGEMENT POLICY

    Oct 1, 2018, 00:00

  • PDB57 - TRENDS IN USE OF DRUGS FOR DIABETES TREATMENT IN SLOVAKIA- REVIEW OF CONSUMPTION DATA FROM 2007 TILL 2017

    Oct 1, 2018, 00:00

  • PSY177 - HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH BETA-THALASSEMIA

    Oct 1, 2018, 00:00

  • PRS74 - ANTI-PNEUMOCOCCAL VACCINATION STRATEGY. STUDY AND PRELIMINARY RWD DECREASING GERIATRICS HOSPITAL ADMISSIONS AND CARE COSTS

    Oct 1, 2018, 00:00

  • PMD21 - PRESSURE INJURIES IN PATIENTS WITH URINARY INCONTINENCE- EFFICACY OF REGENERA, A NEW MEDICAL DEVICE TESTED AT THE OSPEDALE MAGGIORE IN NOVARA

    Oct 1, 2018, 00:00

  • PSS10 - QUANTITATIVE ANALYSIS OF DIABETIC RETINOPATHY (DR) IN THE UK USING ROUTINELY COLLECTED DATA FROM SCREENING PROGRAMME AND HOSPITAL EYE SERVICE (HES) DATABASES

    Oct 1, 2018, 00:00

  • PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE- ISSUES AND WAYS FOR IMPROVEMENT

    Oct 1, 2018, 00:00

  • PMD75 - THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION- EXPLORING THE ITALIAN NATIONAL HEALTH SYSTEM PERSPECTIVE AND CONSIDERING DIFFERENT PATIENTS RISK GROUPS

    Oct 1, 2018, 00:00

  • PCN308 - DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?- A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHES

    Oct 1, 2018, 00:00

  • PGI42 - NON-PERSISTENCE WITH IMMUNOSUPPRESANT, ANTI-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE- A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANY

    Oct 1, 2018, 00:00

  • PND57 - THE COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE MANAGEMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDING

    Oct 1, 2018, 00:00

  • PRS2 - HEALTH OUTCOMES OF MATERNAL SMOKING DURING PREGNANCY AND POSTPARTUM PERIOD FOR THE MOTHER AND INFANT- AN UMBRELLA REVIEW

    Oct 1, 2018, 00:00

  • PIN48 - COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN FOR THE MANAGEMENT OF INVASIVE CANDIDIASIS IN COLOMBIAN ADULTS

    Oct 1, 2018, 00:00

  • PMH30 - MENTAL DISORDERS AND MAJOR DEPRESSION- THE ECONOMIC ANALYSIS OF SOCIAL SECURITY COSTS IN ITALY

    Oct 1, 2018, 00:00

  • PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPAN

    Oct 1, 2018, 00:00

  • AD3 - EVALUATION OF THE “SOPHIA” ASTHMA PATIENT MANAGEMENT PROGRAM AT TWO YEARS

    Oct 1, 2018, 00:00

  • PHP356 - COMPARATIVE ANALYSIS BETWEEN OLD AND NEW ITALIAN INNOVATION RATING SYSTEM

    Oct 1, 2018, 00:00

  • PMD119 - SYSTEMATIC REVIEW ON CLINICAL OUTCOMES OF ULTRASONIC TECHNOLOGY FOR PATIENTS UNDERGOING COLORECTAL ONCOLOGY PROCEDURES

    Oct 1, 2018, 00:00

  • PSY33 - FEASIBILITY OF EVALUATING THE BURDEN OF B-THALASSEMIA WITH GERMAN CLAIMS DATA

    Oct 1, 2018, 00:00

  • PCN276 - MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF)- KEY METRICS AND DRIVERS

    Oct 1, 2018, 00:00

  • Vaccination Programs- Economic and Leadership Considerations

    Oct 1, 2018, 00:00

  • PSY36 - CLINICAL BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW OF INCIDENCE AND DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PRM107 - CAN ACCOUNTING FOR MISSING DATA CAST DOUBT ON PREVIOUS CONCLUSIONS REEVALUATING A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)?

    Oct 1, 2018, 00:00

  • PHP7 - DIGITALIZATION AND CUSTOMER-RESPONSIVE SECONDARY CARE SERVICES POTENTIALLY FREE HEALTH CARE CAPACITY- PREDICTED MONETARY BENEFITS OF VIRTUAL HOSPITAL 2.0

    Oct 1, 2018, 00:00

  • PSY163 - IDENTIFICATION OF KEY ORPHAN DRUG ATTRIBUTES IN PREDICTING THE EXPECTED LEVEL OF PAYER MANAGEMENT IN THE US AND EU3

    Oct 1, 2018, 00:00

  • PMD51 - COMPARISON OF COSTS AND OUTCOMES BETWEEN COBLATION TECHNOLOGY AND ELECTROCAUTERY FOLLOWING TONSILLECTOMY AND ADENOIDECTOMY PROCEDURES

    Oct 1, 2018, 00:00

  • PRM243 - NETWORK META-ANALYSES ON SURVIVAL DATA- A COMPARISON AND GUIDANCE FOR DIFFERENT METHODOLOGIES

    Oct 1, 2018, 00:00

  • PMS37 - INDIRECT COSTS OF VERTEBRAL ALGIC SYNDROME

    Oct 1, 2018, 00:00

  • PMU16 - DISPENSING PATTERNS OF VACCINES IN A PRIVATE HEALTHCARE SETTING IN SOUTH AFRICA

    Oct 1, 2018, 00:00

  • PSY65 - REAL-WORLD DATA ANALYSIS OF US CLAIMS DATA ON COAGULATION FACTOR IX DISPENSATION AND EXPENDITURES IN PATIENTS WITH SEVERE HEMOPHILIA B- STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE PRODUCTS

    Oct 1, 2018, 00:00

  • PIN63 - A COST-MINIMIZATION MODEL TO EVALUATE THE IMPACT OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS IN HOSPITALIZED ADULTS IN SPAIN

    Oct 1, 2018, 00:00

  • PIN68 - COST-EFFECTIVENESS ANALYSIS OF ISAVUCONAZOLE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMD139 - VALUE-BASED PROCUREMENT OF MEDICAL EQUIPMENT IN EUROPE – DID THE 2014 EU DIRECTIVE INFLUENCE TENDERING PRACTICES AND EVIDENCE DEMAND?

    Oct 1, 2018, 00:00

  • PMD142 - WHAT DISCOURAGES ELDERLY USE OF INSULIN-INFUSION PUMPS IN JAPAN?

    Oct 1, 2018, 00:00

  • PND80 - AN OBSERVATIONAL STUDY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS IN FRANCE- FIRST INTERIM ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION FROM THE BRIO STUDY

    Oct 1, 2018, 00:00

  • PSS17 - COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

    Oct 1, 2018, 00:00

  • PCN168 - COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PUK9 - NETWORK META-ANALYSIS OF TREATMENTS IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL-CELL CARCINOMA WITH INTERMEDIATE TO POOR PROGNOSIS

    Oct 1, 2018, 00:00

  • PIN109 - EVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING HIV/AIDS AMONG PREGNANT WOMEN AND THEIR PARTNERS INVOLVED IN PREVENTION MOTHER-TO-CHILD TRANSMISSION (PMTCT) PROGRAMS IN MALAWI.

    Oct 1, 2018, 00:00

  • PRM13 - THE FLAWED RECOMMENDATIONS OF THE SECOND PANEL ON COST-EFFECTIVENESS IN HEALTH AND MEDICINE

    Oct 1, 2018, 00:00

  • PCN265 - END OF LIFE CANCER CHEMOTHERAPY- A RETROSPECTIVE STUDY DURING INTENSIVE CARE UNIT (ICU) STAY

    Oct 1, 2018, 00:00

  • PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PRM210 - METHODS USED TO IDENTIFY PATIENT REPORTED OUTCOME MEASURES IN VASCULAR DISEASES

    Oct 1, 2018, 00:00

  • PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM74 - CLINICAL OUTCOME ASSESSMENTS IN DRUG APPROVALS- A REVIEW OF LABEL CLAIMS IN THE UNITED STATES AND EUROPE (2013-2017)

    Oct 1, 2018, 00:00

  • PND121 - UTILITIES ASSOCIATED WITH ATTRIBUTES OF MIGRAINE PREVENTIVE TREATMENTS- ROUTE OF ADMINISTRATION AND ADVERSE EVENTS

    Oct 1, 2018, 00:00

  • PHP207 - ASSESSMENT OF PHARMACIST MEDICATION CONSULTATION IN COMMUNITY PHARMACIES LOCATED IN TEHRAN

    Oct 1, 2018, 00:00

  • PMU65 - COST-MINIMIZATION ANALYSIS OF SMOFKABIVEN® CENTRAL FOR ADULT PATIENTS WITH IMPOSSIBLE, INSUFFICIENT OR CONTRAINDICATED ORAL OR ENTERAL NUTRITION VERSUS STANDARD ENDOVASCULAR TREATMENT IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PCN98 - PALLIATIVE TREATMENT AND ITS COST IN THE LAST SIX MONTHS OF LIFE FOR METASTATIC COLORECTAL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PSS45 - A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

    Oct 1, 2018, 00:00

  • PHP299 - THREE YEARS OF SINATS

    Oct 1, 2018, 00:00

  • PMS68 - HOSPITAL PHARMACY CENTRALIZED PROCESS FOR HOSPITAL-WIDE MANAGEMENT OF BIOSSIMILARS USE AND ITS EFFICIENCY

    Oct 1, 2018, 00:00

  • PRS72 - A COST ESTIMATION OF MANAGEMENT OF ALLERGIC ASTHMA IN ITALY

    Oct 1, 2018, 00:00

  • PMD10 - PREVALENCE OF UNCONTROLLED BLOOD PRESSURE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM83 - COMPARATIVE ASSSESMENT OF ORAL ANTIDIABETIC DRUG-MEDIATED GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS BETWEEN TWO DIFFERENT REAL-WORLD DATABASES

    Oct 1, 2018, 00:00

  • PUK21 - COST UTILITY ANALYSIS OF END STAGE RENAL DISEASE TREATMENT IN MINISTRY OF HEALTH DIALYSIS CENTRES, MALAYSIA- HAEMODIALYSIS VERSUS CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

    Oct 1, 2018, 00:00

  • PRM112 - INCORPORATION OF ANTI-CANCER DRUGS ADVERSE EVENTS IN HEALTH ECONOMIC OPINIONS OF THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Oct 1, 2018, 00:00

  • PHP310 - COMPARISON OF THE HEALTH TECHNOLOGY ASSESSMENT OFFICES OF HUNGARY AND POLAND BASED ON OBJECTIVE CRITERIA

    Oct 1, 2018, 00:00

  • PMS105 - EXAMINATION OF CORE TRAINING PROGRAM ON THE CHANGE OF LOW BACK PAIN, MUSCLE STRENGTH AND LUMBAR MOTOR CONTROLL AMONG PROFESSIONAL FIREFIGHTERS

    Oct 1, 2018, 00:00

  • PRM202 - COMPARING THE EQ-5D-5L CROSSWALKS AND VALUE SETS FOR ENGLAND, THE NETHERLANDS AND SPAIN- DO CONCLUSIONS CHANGE?

    Oct 1, 2018, 00:00

  • PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PRS93 - THE HEALTH-RELATED QUALITY OF LIFE BURDEN OF PEANUT ALLERGY IN ADULTS, ADOLESCENTS AND CHILDREN IN THE UK

    Oct 1, 2018, 00:00

  • PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIA

    Oct 1, 2018, 00:00

  • PMD152 - HEALTHCARE RESOURCE UTILIZATION, COMPLICATIONS AND COSTS FOR OPEN REDUCTION INTERNAL FIXATION OF THE FEMUR, TIBIA AND FIBULA

    Oct 1, 2018, 00:00

  • PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARS

    Oct 1, 2018, 00:00

  • PRM26 - TIME TO DETERIORATION (TTD) IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN NSCLC PATIENTS- A REVIEW OF DEFINITIONS

    Oct 1, 2018, 00:00

  • PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDY

    Oct 1, 2018, 00:00

  • PCN149 - COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPAN

    Oct 1, 2018, 00:00

  • PSY119 - TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCE CONSUMPTION ON PATIENTS AFFECTED BY PSORIASIS IN APULIA REGION (ITALY).

    Oct 1, 2018, 00:00

  • PMD116 - UTILISATION AND ECONOMIC BURDEN OF FLOWABLE HEMOSTATIC AGENTS IN GERMAN HOSPITALS- A REAL-WORLD PATIENT CHART REVIEW STUDY

    Oct 1, 2018, 00:00

  • PMH25 - EARLY ADMINISTRATION OF ARIPIPRAZOLE LONG-ACTING INJECTABLE IN ACUTE INPATIENTS WITH SCHIZOPHRENIA REDUCES THE COST OF HOSPITALIZATION

    Oct 1, 2018, 00:00

  • PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPE

    Oct 1, 2018, 00:00

  • PRS79 - MODELING THE POPULATION YEARS OF LIFE SAVED BY INTRODUCING A REDUCED-RISK PRODUCT IN THE U.S. AND IN JAPAN

    Oct 1, 2018, 00:00

  • PSS49 - EPIDEMIOLOGY AND TREATMENT PATTERNS IN ADULT PATIENTS WITH ATOPIC DERMATITIS- ANALYSIS OF LONGITUDINAL DATA FROM THE GERMAN STATUTORY HEALTH INSURANCE SYSTEM

    Oct 1, 2018, 00:00

  • PCP56 - EARLY ACCESS PROGRAMS- RECOMMENDATIONS FOR REAL-WORLD DATA COLLECTION

    Oct 1, 2018, 00:00

  • PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?

    Oct 1, 2018, 00:00

  • PSS19 - IMPORTANCE OF THE OUT-OF-POCKET COST FOR ATOPIC DERMATITIS AFFECTED ADULTS

    Oct 1, 2018, 00:00

  • PSY160 - REAL WORLD TREATMENT PATTERNS AND RESOURCE UTILIZATION IN PULMONARY ARTERIAL HYPERTENSION IN BRAZIL- A PUBLIC HEALTHCARE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PIN128 - INSUFFICIENT DECLINE IN HIV PREVALENCE AMIDST HIGH SCORES IN HIV TESTING AND AWARENESS- A LOGISTIC MODELLING FOR HIV PREVALENCE INFORMATION AND INDIVIDUAL PROTECTIVE BEHAVIOURS IN UGANDA

    Oct 1, 2018, 00:00

  • Economic Analysis of Vaccination Programs

    Oct 1, 2018, 00:00

  • CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATA

    Oct 1, 2018, 00:00

  • PCN289 - HOW ACCELARATED IS PATIENTS’ ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG’S FUND IN ENGLAND?

    Oct 1, 2018, 00:00

  • PMS84 - COMPARISON OF HTA ASSESSMENTS OF SARILUMAB IN DIFFERENT SUBPOPULATIONS FOR RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PMD105 - EVALUATING THE COST-EFFECTIVENESS OF SCREENING FOR THE GENETIC RISK OF THROMBOSIS DURING THE RECOMMENDATION OF COMBINED HORMONAL CONTRACEPTION FOR FIRST-TIME USERS IN SWITZERLAND

    Oct 1, 2018, 00:00

  • PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS- APPLY LIBERALLY OR USE SPARINGLY?

    Oct 1, 2018, 00:00

  • PMS82 - HOW DO HEALTH SYSTEM EMPLOYEES WITH ESTABLISHED MUSCULOSKELETAL COMPLAINTS DECIDE ON THEIR TREATMENT PATHWAY? A QUALITATIVE APPROACH

    Oct 1, 2018, 00:00

  • PIN47 - THE POTENTIAL ROLE OF COST-EFFECTIVENESS ANALYSIS AND INCREMENTAL COST-EFFECTIVENESS RATIO THRESHOLDS IN THE UNITED STATES CENTERS FOR DISEASE CONTROL AND PREVENTION’S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (CDC ACIP) VACCINAT ...

    Oct 1, 2018, 00:00

  • PCV147 - A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITIES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PRS52 - COST-MINIMIZATION ANALYSIS OF SQ® HDM SLIT-TABLET IN PATIENTS WITH HOUSE DUST MITE ALLERGIC RHINITIS WITH OR WITHOUT ALLERGIC ASTHMA IN POLAND

    Oct 1, 2018, 00:00

  • PSY158 - A PRAGMATIC LITERATURE REVIEW TO IDENTIFY ECONOMIC OUTCOMES FOR REPURPOSED DRUGS IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PMU105 - PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMENT- A SYSTEMATIC REVIEW AND RESEARCH AGENDA

    Oct 1, 2018, 00:00

  • PND8 - PEGINTERFERON BETA-1A IS ASSOCIATED WITH REDUCED RELAPSE RATES AND HOSPITALISATIONS DUE TO RELAPSE COMPARED WITH OTHER FIRST-LINE INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTING

    Oct 1, 2018, 00:00

  • PMD94 - ECONOMIC EVALUATION OF ACCU-CHEK ® INSTANT S GLUCOMETER FOR THE SELF-MONITORING GLUCOSE (SMG) IN PATIENTS WITH DIABETES MELLITUS (DM), FROM THE VIEW OF THE PUBLIC HEALTHCARE SYSTEM IN MEXICO.

    Oct 1, 2018, 00:00

  • PMD108 - COST-EFFECTIVENESS OF LEFT VENTRICULAR ASSIST DEVICES IN END STAGE HEART FAILURE USING STATE TRANSITION MODELLING BASED ON REGISTRY DATA

    Oct 1, 2018, 00:00

  • PUK24 - HYPERKALAEMIA IN CHRONIC KIDNEY DISEASE- PATIENT TREATMENT EXPERIENCE WITH RENIN-ANGIOTENSIN-ALDOSTERONE- SYSTEM INHIBITORS IN PRIMARY CARE IN ENGLAND

    Oct 1, 2018, 00:00

  • PRM262 - TRENDS IN DRUG PRICES BEFORE AND AFTER GENERIC COMPETITION IN THE US (2014-2016)

    Oct 1, 2018, 00:00

  • AD1 - ASSOCIATION OF ADHERENCE AND TREATMENT INTENSITY WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ATHEROSCLEROSIS OR OTHER CARDIOVASCULAR RISK FACTORS TREATED WITH STATINS AND/OR EZETIMIBE

    Oct 1, 2018, 00:00

  • PRM216 - AGREEMENT BETWEEN REVISED BRUNET-LÉZINE AND INTERGROWTH-21ST NEURODEVELOPMENTAL ASSESSMENTS

    Oct 1, 2018, 00:00

  • PRM247 - META-ANALYSES USING REAL-WORLD DATA- A SYSTEMATIC LITERATURE REVIEW OF EXISTING RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PND47 - ECONOMIC BURDEN OF ALZHEIMER’S DISEASE IN THE UK

    Oct 1, 2018, 00:00

  • PMH45 - MODELLING THE BUDGETARY IMPACT OF TREATING OPIOID ADDICTION IN THE ENGLISH MUNICIPAL SETTING

    Oct 1, 2018, 00:00

  • PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PMS116 - HUMANISTIC AND ECONOMIC BURDEN OF X-LINKED HYPOPHOSPHATEMIA (XLH)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITAL

    Oct 1, 2018, 00:00

  • PSY69 - THE BURDEN OF HYPERKALEMIA IN GERMANY – A CLAIMS DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PMD180 - THE VALUE TO WOMEN WITH OVARIAN CANCER OF GENE VARIANTS WITH KNOWN AND UNKNOWN SIGNIFICANCE- A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PSY123 - IDENTIFICATION OF THE TREATMENT ATTRIBUTES TO BE CONSIDERED IN SHARED DECISION MAKING FOR ANKYLOSING SPONDYLITIS PATIENTS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY135 - ACCESS TO ORPHAN DRUGS – REGULATION WITHIN THE EUROPEAN LAW

    Oct 1, 2018, 00:00

  • PMH16 - THE PRESCRIPTION PATTERNS OF SELECTIVE SEROTONIN (NOREPINEPHRINE) REUPTAKE INHIBITORS IN GERMANY

    Oct 1, 2018, 00:00

  • PUK13 - THE TREATMENT OF IRON DEFICIENCY/ANAEMIA IN PATIENTS WITH NON-DIALYSIS CHRONIC KIDNEY DISEASE IN GERMANY – A CLAIMS DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PUK18 - ECONOMIC EVALUATION OF THE USE OF SEVELAMER (RIFOSAR®) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL DISEASE, FROM THE PERSPECTIVE OF THE INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)

    Oct 1, 2018, 00:00

  • PMU125 - EVALUATING THE INFLUENCE OF SHARED DECISION-MAKING ON PATIENTS' HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE GENERAL-OUTPATIENT CLINIC IN HONG KONG SAR, CHINA

    Oct 1, 2018, 00:00

  • PIN79 - ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE- A REAL-WORLD-BASED ANALYSIS FROM PITER DATA

    Oct 1, 2018, 00:00

  • PCN302 - IS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY INDICATIONS TOO POSITIVE IN ITS ASSESSMENT OF CANCER DRUGS IN ENGLAND?

    Oct 1, 2018, 00:00

  • PUK19 - COST-UTILITY OF SUCROFERRIC OXYHYDROXIDE FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN CANADA

    Oct 1, 2018, 00:00

  • PHP112 - DO PATIENTS KNOW ABOUT THEIR CHRONIC HEALTH PROBLEMS AND THE DRUGS THEY TAKE?

    Oct 1, 2018, 00:00

  • PCP9 - GENE THERAPY CRISIS- HOW WILL THE CURRENT PRODUCT PIPELINE AFFECT THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE SYSTEMS?

    Oct 1, 2018, 00:00

  • PRS69 - IMPACT OF THE INTERNATIONAL REFERENCE PRICING ON ACCESS TO STANDARD THERAPY DRUGS FOR COPD

    Oct 1, 2018, 00:00

  • PRM268 - EVALUATION OF REAL-WORLD DATA COLLECTION AND EVIDENCE GENERATION FROM EARLY ACCESS PROGRAM

    Oct 1, 2018, 00:00

  • PRM229 - THE CLUSTERED NATURE OF TRIAL-BASED ECONOMIC EVALUATIONS- DOES IT MATTER?

    Oct 1, 2018, 00:00

  • PSY92 - ECONOMIC AND PATIENT OUTCOMES OF GENERIC AND BRAND-NAME STATINS USED IN ROUTINE CLINICAL PRACTICE IN SPAIN

    Oct 1, 2018, 00:00

  • PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS- A SURVIVAL MODEL ANALYSIS

    Oct 1, 2018, 00:00

  • PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELAND

    Oct 1, 2018, 00:00

  • PMD90 - ECONOMIC EVALUATION OF THE IMMUNOCYTOCHEMISTRY TEST FOR THE SIMULTANEOUS QUALITATIVE DETECTION OF PROTEINS P16INKA AND KI-67 (CINTEC PLUS CYTOLOGY KIT®) IN CERVICAL TISSUE

    Oct 1, 2018, 00:00
  • «
  • 61
  • 62 (current)
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • »